SCHEMBL5356271

SCHEMBL5356271

O=C(O)c1sccc1S(=O)(=O)NCCc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.50
POLB P06746 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 1/20 0.46
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
EDNRA P25101 1/20 0.44
LMNA P02545 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FABP4 P15090 2/20 0.43
SGMS1 Q86VZ5 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5354487 0.86 ALDH1A1 (0.54) TAAR1POLBCYP1A2CYP2D6CYP2C19
SCHEMBL5356604 0.76 LMNA (0.46) TAAR1MEN1CYP3A4TSHRKMT2A
SCHEMBL5352377 0.74 SMN1; SMN2 (0.39) CYP1A2CYP2D6CYP2C19ALDH1A1MEN1
SCHEMBL11106576 0.70 TBXA2R (0.75) TAAR1POLBCYP1A2CYP2D6CYP2C19
SCHEMBL11532397 0.70 LMNA (0.62) ALDH1A1MEN1CYP3A4TSHRKMT2A
SCHEMBL5354260 0.69 KCNH2 (0.45) POLBCYP1A2CYP2D6CYP2C19ALDH1A1
SCHEMBL10463511 0.68 TAAR1 (0.72) TAAR1POLBCYP1A2CYP2D6CYP2C19
SCHEMBL5356280 0.68 KMT2A (0.51) POLBTDP1MEN1TSHRKMT2A
SCHEMBL13073499 0.67 TAAR1 (1.00) TAAR1POLBCYP1A2CYP2D6CYP2C19
SCHEMBL11116844 0.67 MEN1 (0.56) MEN1CYP3A4TSHRKMT2AEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 TAAR1 675/4885POLB 4113/4885CYP1A2 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.